/EVAX
EVAX Stock - Evaxion Biotech A/S
Healthcare|BiotechnologyNASDAQ
$4.70-18.26%
$1.05 (-18.26%) • Dec 19
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+187.2%upside
Target: $13.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EVAX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.65 – $4.75
TARGET (TP)$13.50
STOP LOSS$4.32
RISK/REWARD1:23.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.28
52W High$12.15
52W Low$1.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $3.34M | $73,000 | N/A | N/A | N/A |
| Gross Profit | $3.34M | $73,000 | N/A | N/A | N/A |
| Gross Margin | 100.0% | 100.0% | N/A | N/A | N/A |
| Operating Income | $-14,732,000 | $-22,197,000 | $-25,264,000 | $-25,834,000 | $-16,568,000 |
| Net Income | $-10,567,000 | $-22,125,000 | $-23,169,000 | $-24,532,000 | $-15,018,000 |
| Net Margin | -316.0% | -30308.2% | N/A | N/A | N/A |
| EPS | $-9.80 | $-32.40 | $-39.20 | $-50.40 | $-37.00 |
Company Overview
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 134.0% Upside
Now
$8
Low
$11
Average
$14
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 2nd 2024 | Ladenburg Thalmann | Upgrade | Buy | $8 |
| February 12th 2024 | H.C. Wainwright | Initiation | Buy | $14 |
Earnings History & Surprises
EVAXBeat Rate
50%
Last 18 quarters
Avg Surprise
-937.4%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$0.73
Q4 2025
EPS Surprise History
Q1 24
+50.0%
$-0.80vs$-1.60
Q2 24
+126.8%
$0.15vs$-0.56
Q3 24
-700.0%
$-0.60vs$0.10
Q4 24
+66.7%
$-0.20vs$-0.60
Q1 25
-207.7%
$-0.80vs$-0.26
Q2 25
+55.4%
$-0.29vs$-0.65
Q3 25
-52.0%
$-0.76vs$-0.50
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 7, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | — | $0.73 | — | — |
Q3 2025 | Aug 14, 2025 | $-0.50 | $-0.76 | -52.0% | ✗ MISS |
Q2 2025 | May 27, 2025 | $-0.65 | $-0.29 | +55.4% | ✓ BEAT |
Q1 2025 | Mar 26, 2025 | $-0.26 | $-0.80 | -207.7% | ✗ MISS |
Q4 2024 | Oct 31, 2024 | $-0.60 | $-0.20 | +66.7% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $0.10 | $-0.60 | -700.0% | ✗ MISS |
Q2 2024 | May 28, 2024 | $-0.56 | $0.15 | +126.8% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-1.60 | $-0.80 | +50.0% | ✓ BEAT |
Q4 2023 | Dec 19, 2023 | $-0.19 | $-10.50 | -5426.3% | ✗ MISS |
Q3 2023 | Aug 18, 2023 | $-0.21 | $-10.50 | -4900.0% | ✗ MISS |
Q2 2023 | Apr 27, 2023 | $-0.24 | $-14.50 | -5941.7% | ✗ MISS |
Q1 2023 | Mar 28, 2023 | $-0.28 | $-0.39 | -39.3% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-17.00 | $-12.00 | +29.4% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-16.50 | $-10.00 | +39.4% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-17.50 | $-12.50 | +28.6% | ✓ BEAT |
Q1 2022 | Mar 22, 2022 | $-15.00 | $-19.50 | -30.0% | ✗ MISS |
Q4 2021 | Nov 9, 2021 | $-0.34 | $-0.27 | +20.6% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.29 | $-0.36 | -24.1% | ✗ MISS |
Q2 2021 | May 13, 2021 | $-16.50 | $-11.50 | +30.3% | ✓ BEAT |
Latest News
Evaxion Says MSD Declines EVX-B2 Option, Returning Global Gonorrhea Vaccine Rights To Evaxion With Cash Runway Unchanged Into Second Half Of 2027
➖ NeutralBenzinga•Dec 19, 2025, 12:04 PM
Evaxion shares are trading higher after the company announced new data for EVX-04.
📈 PositiveBenzinga•Dec 8, 2025, 05:14 PM
Reported Saturday, Evaxion Announces EVX-04 Triggers Specific Immune Responses Across 16 Selected ERV Fragments And Supports Broad Tumor Coverage For Acute Myeloid Leukemia
📈 PositiveBenzinga•Dec 8, 2025, 08:49 AM
Evaxion Advances Multi-Component Cytomegalovirus Vaccine Program, EVX-V1, With New Data Demonstrating Protective Effects Of Lead Antigens
📈 PositiveBenzinga•Nov 20, 2025, 01:04 PM
Evaxion Announces New Data Exploring Immune Responses Following Treatment With AI-designed Personalized Cancer Vaccine EVX-01
📈 PositiveBenzinga•Nov 7, 2025, 10:16 PM
Evaxion Biotech Q3 EPS $0.01 Beats $(0.21) Estimate, Sales $7.492M Beat $2.500M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:32 PM
Evaxion Expands R&D Pipeline With Addition EVX-04, AI-Designed Precision Cancer Vaccine Candidate
📈 PositiveBenzinga•Nov 3, 2025, 02:10 PM
Edward Jones Initiates Coverage On Evaxion with Buy Rating, Announces Price Target of $10
📈 PositiveBenzinga•Oct 30, 2025, 12:55 PM
Evaxion Says Has Raised $7.2M In Recent Weeks, Extending Cash Runway To 2H 2027
📈 PositiveBenzinga•Oct 30, 2025, 12:08 PM
Evaxion A/S Appoints Helen Tayton-Martin CEO, Effective Nov. 24
➖ NeutralBenzinga•Oct 27, 2025, 12:05 PM
Lake Street Maintains Buy on Evaxion, Raises Price Target to $11
📈 PositiveBenzinga•Oct 20, 2025, 01:16 PM
HC Wainwright & Co. Reiterates Buy on Evaxion, Maintains $16 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 12:01 PM
Evaxion shares are trading lower. The company announced new two-year unprecedented clinical efficacy data of its personalized cancer vaccine EVX-01 in patients with advanced melanoma.
➖ NeutralBenzinga•Oct 17, 2025, 02:31 PM
Evaxion A/S Reports Two-Year Phase 2 Data Showing Results For Its Personalized Cancer Vaccine EVX-01 In Advanced Melanoma. Study Showed A 75% Objective Response Rate With 4 Of 16 Patients Achieving Complete Responses And 92% Maintaining Durable Responses At 24 Months With No Relapses
📈 PositiveBenzinga•Oct 17, 2025, 12:21 PM
Evaxion Will Present Comprehensive Phase 2 Trial Data For Its Lead Cancer Vaccine EVX-01 At The ESMO Congress 2025 In Berlin Oct 17–21, 2025.
📈 PositiveBenzinga•Oct 13, 2025, 12:09 PM
Evaxion To Present New Biomarker And Immune Data From Ongoing Phase 2 Trial With EVX-01 At SITC 2025 Annual Meeting
📈 PositiveBenzinga•Oct 3, 2025, 01:02 PM
HC Wainwright & Co. Maintains Buy on Evaxion, Raises Price Target to $16
📈 PositiveBenzinga•Sep 25, 2025, 03:43 PM
Market-Moving News for September 25th
➖ NeutralBenzinga•Sep 25, 2025, 11:24 AM•Also: ,
Evaxion shares are trading higher after the company out-licensed its EVX-B3 vaccine candidate to MSD for a $7.5 million cash payment, up to $592 million in milestones and royalties on sales.
📈 PositiveBenzinga•Sep 25, 2025, 11:05 AM
Evaxion Out-Licenses Vaccine Candidate EVX-B3 To MSD; Co. Will Receive $7.5M Cash Payment And Up To $592M In Milestones As Well As Royalties On Sales
📈 PositiveBenzinga•Sep 25, 2025, 11:05 AM
Frequently Asked Questions about EVAX
What is EVAX's current stock price?
Evaxion Biotech A/S (EVAX) is currently trading at $4.70 per share. The stock has moved -18.26% today.
What is the analyst price target for EVAX?
The average analyst price target for EVAX is $13.50, based on 1 analyst.
What sector is Evaxion Biotech A/S in?
Evaxion Biotech A/S operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is EVAX's market cap?
Evaxion Biotech A/S has a market capitalization of $0.03 billion, making it a small-cap company.
Does EVAX pay dividends?
No, Evaxion Biotech A/S does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
BTAI
BioXcel Therapeutics, Inc.
$1.73
Mkt Cap: $0.0B
CELU
Celularity Inc.
$1.45
Mkt Cap: $0.0B
GBIO
Generation Bio Co.
$5.54
Mkt Cap: $0.0B
MURA
Mural Oncology plc
$2.04
Mkt Cap: $0.0B
PYPD
PolyPid Ltd.
$3.97
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
VERU
Veru Inc.
$2.32
Mkt Cap: $0.0B
Explore stocks similar to EVAX for comparison